108 related articles for article (PubMed ID: 18640440)
1. Apolipoprotein B/A1 and risk of cardiovascular disease.
Lind L
Lancet; 2008 Jul; 372(9634):185-6. PubMed ID: 18640440
[No Abstract] [Full Text] [Related]
2. Apolipoproteins A-I and B-markers in coronary risk evaluation.
Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of apolipoproteins A1 and B in survivors of myocardial infarction.
Jadhav PP; Taskar AP; Taskar SP; Darne RD
J Assoc Physicians India; 1994 Sep; 42(9):703-5. PubMed ID: 7883664
[TBL] [Abstract][Full Text] [Related]
4. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy.
Walldius G; Jungner I
Eur Heart J; 2005 Feb; 26(3):210-2. PubMed ID: 15618031
[No Abstract] [Full Text] [Related]
5. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM).
Dunder K; Lind L; Zethelius B; Berglund L; Lithell H
Am Heart J; 2004 Oct; 148(4):596-601. PubMed ID: 15459588
[TBL] [Abstract][Full Text] [Related]
6. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
Walldius G; Jungner I; Holme I; Aastveit AH; Kolar W; Steiner E
Lancet; 2001 Dec; 358(9298):2026-33. PubMed ID: 11755609
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein B/apolipoprotein A-I ratio and apolipoprotein B: long-term predictors of myocardial infarction in initially healthy middle-aged men--a 13-year follow-up.
Schmidt C; Bergström G
Angiology; 2014 Nov; 65(10):901-5. PubMed ID: 24277914
[TBL] [Abstract][Full Text] [Related]
8. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men.
Lind L; Vessby B; Sundström J
Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):406-10. PubMed ID: 16306426
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study.
Pitsavos C; Panagiotakos DB; Skoumas J; Papadimitriou L; Stefanadis C
Angiology; 2008; 59(3):335-41. PubMed ID: 18388068
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotiens and prediction of fatal myocardial infarction.
Wald NJ; Law M; Haddow JE; Craig WY
Lancet; 2002 May; 359(9320):1864. PubMed ID: 12044410
[No Abstract] [Full Text] [Related]
11. Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk.
Raitakari OT; Mäkinen VP; McQueen MJ; Niemi J; Juonala M; Jauhiainen M; Salomaa V; Hannuksela ML; Savolainen MJ; Kesäniemi YA; Kovanen PT; Sundvall J; Solakivi T; Loo BM; Marniemi J; Hernesniemi J; Lehtimäki T; Kähönen M; Peltonen M; Leiviskä J; Jula A; Anand SS; Miller R; Yusuf S; Viikari JS; Ala-Korpela M
Atherosclerosis; 2013 Jan; 226(1):245-51. PubMed ID: 23159013
[TBL] [Abstract][Full Text] [Related]
12. Apo-B/AI ratio identifies cardiovascular risk in childhood: the Australian Aboriginal Birth Cohort study.
Sellers EA; Singh GR; Sayers SM
Diab Vasc Dis Res; 2009 Apr; 6(2):94-9. PubMed ID: 20368199
[TBL] [Abstract][Full Text] [Related]
13. Low diurnal variability of apolipoprotein A1, apolipoprotein B and apolipoprotein B/apolipoprotein A1 ratio during normal sleep and after an acute shift of sleep.
Larsson A; Carlsson L; Axelsson J
Clin Biochem; 2008 Jul; 41(10-11):859-62. PubMed ID: 18387362
[TBL] [Abstract][Full Text] [Related]
14. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?
Jungner I; Sniderman AD; Furberg C; Aastveit AH; Holme I; Walldius G
Am J Cardiol; 2006 Apr; 97(7):943-6. PubMed ID: 16563891
[TBL] [Abstract][Full Text] [Related]
15. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
16. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence.
Walldius G; Jungner I
J Intern Med; 2006 May; 259(5):493-519. PubMed ID: 16629855
[TBL] [Abstract][Full Text] [Related]
17. [Apolipoproteins are new and better risk indicators of myocardial infarction].
Walldius G; Jungner I
Lakartidningen; 2004 Mar; 101(13):1188-94. PubMed ID: 15101244
[TBL] [Abstract][Full Text] [Related]
18. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
Faergeman O
J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
[No Abstract] [Full Text] [Related]
19. [Should apolipoproteins be the first choice in routine health care?].
Järhult B; Lindström K
Lakartidningen; 2007 Oct 17-23; 104(42):3124. PubMed ID: 17985715
[No Abstract] [Full Text] [Related]
20. Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack.
Bhatia M; Howard SC; Clark TG; Neale R; Qizilbash N; Murphy MF; Rothwell PM
Cerebrovasc Dis; 2006; 21(5-6):323-8. PubMed ID: 16490941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
